Siegel R.L. Miller K.D. Fuchs H.E. et al.

Cancer Statistics, 2021.

CA Cancer J Clin. 71: 7-33

Epidemiology of Prostate Cancer.

World J Oncol. 10: 63-89Fitzmaurice C. Abate D. Abbasi N. et al.

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study.

JAMA Oncol. 5: 1749-1768Hugosson J. Roobol M.J. Mansson M. et al.

A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.

Eur Urol. 76: 43-51Schroder F.H. Hugosson J. Roobol M.J. et al.

Prostate-cancer mortality at 11 years of follow-up.

N Engl J Med. 366: 981-990Schroder F.H. Hugosson J. Roobol M.J. et al.

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Lancet. 384: 2027-2035Fenton J.J. Weyrich M.S. Durbin S. et al.

Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.

JAMA. 319: 1914-1931Loeb S. Bjurlin M.A. Nicholson J. et al.

Overdiagnosis and overtreatment of prostate cancer.

Eur Urol. 65: 1046-1055Loeb S. Vellekoop A. Ahmed H.U. et al.

Systematic review of complications of prostate biopsy.

Eur Urol. 64: 876-892National Comprehensive Cancer Network

Prostate Cancer Early Detection Guidelines.

() ()Drost F.H. Osses D.F. Nieboer D. et al.

Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer.

Cochrane Database Syst Rev. 4: CD012663Bass E.J. Pantovic A. Connor M.J. et al.

Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis.

Prostate Cancer Prostatic Dis. 25: 174-179Sathianathen N.J. Omer A. Harriss E. et al.

Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis.

Eur Urol. 78: 402-414Eyrich N.W. Morgan T.M. Tosoian J.J.

Biomarkers for detection of clinically significant prostate cancer: contemporary clinical data and future directions.

Transl Androl Urol. 10: 3091-3103McDonald M.L. Parsons J.K.

4-Kallikrein Test and Kallikrein Markers in Prostate Cancer Screening.

Urol Clin North Am. 43: 39-46Stattin P. Vickers A.J. Sjoberg D.D. et al.

Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.

Eur Urol. 68: 207-213Vickers A. Vertosick E.A. Sjoberg D.D. et al.

Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis.

J Urol. 199: 1470-1474Punnen S. Nahar B. Soodana-Prakash N. et al.

Optimizing patient's selection for prostate biopsy: A single institution experience with multi-parametric MRI and the 4Kscore test for the detection of aggressive prostate cancer.

PLoS One. 13: e0201384Parekh D.J. Punnen S. Sjoberg D.D. et al.

A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.

Eur Urol. 68: 464-470Ahmed H.U. El-Shater Bosaily A. Brown L.C. et al.

Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.

Lancet. 389: 815-822Marzouk K. Ehdaie B. Vertosick E. et al.

Developing an effective strategy to improve the detection of significant prostate cancer by combining the 4Kscore and multiparametric MRI.

Urol Oncol. 37: 672-677Falagario U.G. Martini A. Wajswol E. et al.

Avoiding Unnecessary Magnetic Resonance Imaging (MRI) and Biopsies: Negative and Positive Predictive Value of MRI According to Prostate-specific Antigen Density, 4Kscore and Risk Calculators.

Eur Urol Oncol. 3: 700-704de la Calle C.M. Fasulo V. Cowan J.E. et al.

Clinical Utility of 4Kscore((R)), ExosomeDx and Magnetic Resonance Imaging for the Early Detection of High Grade Prostate Cancer.

J Urol. 205: 452-460McKiernan J. Donovan M.J. O'Neill V. et al.

A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.

JAMA Oncol. 2: 882-889McKiernan J. Donovan M.J. Margolis E. et al.

A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.

Eur Urol. 74: 731-738Falagario U.G. Lantz A. Jambor I. et al.

Using biomarkers in patients with positive multiparametric magnetic resonance imaging: 4Kscore predicts the presence of cancer outside the index lesion.

Int J Urol. 28: 47-52de la Calle C. Patil D. Wei J.T. et al.

Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naive Men.

J Urol. 194: 65-72Nordstrom T. Vickers A. Assel M. et al.

Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.

Eur Urol. 68: 139-146Seisen T. Roupret M. Brault D. et al.

Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy.

Prostate. 75: 103-111Chiu P.K. Ng C.F. Semjonow A. et al.

A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings.

Eur Urol. 75: 558-561

United States Food and Drug Administration. 2022.

() ()Gnanapragasam V.J. Burling K. George A. et al.

The Prostate Health Index adds predictive value to multi-parametric MRI in detecting significant prostate cancers in a repeat biopsy population.

Sci Rep. 6: 35364Tosoian J.J. Druskin S.C. Andreas D. et al.

Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice.

Prostate Cancer Prostatic Dis. 20: 228-233Carbunaru S. Stinson J. Babajide R. et al.

Performance of prostate health index and PSA density in a diverse biopsy-naive cohort with mpMRI for detecting significant prostate cancer.

BJUI Compass. 2: 370-376Fan Y.H. Pan P.H. Cheng W.M. et al.

The Prostate Health Index aids multi-parametric MRI in diagnosing significant prostate cancer.

Sci Rep. 11: 1286Haese A. Trooskens G. Steyaert S. et al.

Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer before Initial Prostate Biopsy.

J Urol. 202: 256-263Maggi M. Del Giudice F. Falagario U.G. et al.

SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study.

Cancers (Basel). 13Busetto G.M. Del Giudice F. Maggi M. et al.

Prospective assessment of two-gene urinary test with multiparametric magnetic resonance imaging of the prostate for men undergoing primary prostate biopsy.

World J Urol. 39: 1869-1877Hendriks R.J. van der Leest M.M.G. Israel B. et al.

Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naive men.

Prostate Cancer Prostatic Dis. 24: 1110-1119Morote J. Diaz F. Celma A. et al.

Behavior of SelectMDx and Prostate-specific Antigen Density in the Challenging Scenario of Prostate Imaging-Reporting and Data System Category 3 Lesions.

Eur Urol. 81: 124-125Tomlins S.A. Day J.R. Lonigro R.J. et al.

Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.

Eur Urol. 70: 45-53Tosoian J.J. Trock B.J. Morgan T.M. et al.

Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach.

J Urol. 205: 732-739Tosoian J.J. Singhal U. Davenport M.S. et al.

Urinary MyProstateScore (MPS) to Rule out Clinically-Significant Cancer in Men with Equivocal (PI-RADS 3) Multiparametric MRI: Addressing an Unmet Clinical Need.

Urology. 164: 184-190Vickers A.J. Van Calster B. Steyerberg E.W.

Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests.

BMJ. 352: i6Schoots I.G. Osses D.F. Drost F.H. et al.

Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease.

Transl Androl Urol. 7: 132-144Filson C.P. Natarajan S. Margolis D.J. et al.

Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies.

Cancer. 122: 884-892Pokorny M.R. de Rooij M. Duncan E. et al.

Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.

Eur Urol. 66: 22-29Venderink W. van Luijtelaar A. Bomers J.G.R. et al.

Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate Cancer.

Eur Urol. 73: 353-360

MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions?.

Transl Androl Urol. 7: 70-82Stevens E. Truong M. Bullen J.A. et al.

Clinical utility of PSAD combined with PI-RADS category for the detection of clinically significant prostate cancer.

Urol Oncol. 38: 846.e9-846.e16